195 related articles for article (PubMed ID: 1899909)
1. The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein.
Buss JE; Quilliam LA; Kato K; Casey PJ; Solski PA; Wong G; Clark R; McCormick F; Bokoch GM; Der CJ
Mol Cell Biol; 1991 Mar; 11(3):1523-30. PubMed ID: 1899909
[TBL] [Abstract][Full Text] [Related]
2. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.
Cox AD; Hisaka MM; Buss JE; Der CJ
Mol Cell Biol; 1992 Jun; 12(6):2606-15. PubMed ID: 1375323
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous amino acids in Ras and Rap1A specifying sensitivity to GAP proteins.
Zhang K; Papageorge AG; Martin P; Vass WC; Olah Z; Polakis PG; McCormick F; Lowy DR
Science; 1991 Dec; 254(5038):1630-4. PubMed ID: 1749934
[TBL] [Abstract][Full Text] [Related]
4. Transient palmitoylation supports H-Ras membrane binding but only partial biological activity.
Coats SG; Booden MA; Buss JE
Biochemistry; 1999 Sep; 38(39):12926-34. PubMed ID: 10504264
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of baculovirus-expressed rap1A/Krev-1 and its regulation by GTPase-activating proteins.
Quilliam LA; Der CJ; Clark R; O'Rourke EC; Zhang K; McCormick F; Bokoch GM
Mol Cell Biol; 1990 Jun; 10(6):2901-8. PubMed ID: 2160589
[TBL] [Abstract][Full Text] [Related]
6. Rap1A antagonizes the ability of Ras and Ras-Gap to inhibit muscarinic K+ channels.
Yatani A; Quilliam LA; Brown AM; Bokoch GM
J Biol Chem; 1991 Nov; 266(33):22222-6. PubMed ID: 1939245
[TBL] [Abstract][Full Text] [Related]
7. Generation of specific antibodies against the rap1A, rap1B and rap2 small GTP-binding proteins. Analysis of rap and ras proteins in membranes from mammalian cells.
Klinz FJ; Seifert R; Schwaner I; Gausepohl H; Frank R; Schultz G
Eur J Biochem; 1992 Jul; 207(1):207-13. PubMed ID: 1628649
[TBL] [Abstract][Full Text] [Related]
8. Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location.
Hart KC; Donoghue DJ
Oncogene; 1997 Feb; 14(8):945-53. PubMed ID: 9050994
[TBL] [Abstract][Full Text] [Related]
9. The residues of Ras and Rap proteins that determine their GAP specificities.
Maruta H; Holden J; Sizeland A; D'Abaco G
J Biol Chem; 1991 Jun; 266(18):11661-8. PubMed ID: 1828804
[TBL] [Abstract][Full Text] [Related]
10. Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid.
Kinsella BT; Erdman RA; Maltese WA
Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8934-8. PubMed ID: 1924354
[TBL] [Abstract][Full Text] [Related]
11. Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with ras-dependent activation of Raf-1.
Hu CD; Kariya Ki; Kotani G; Shirouzu M; Yokoyama S; Kataoka T
J Biol Chem; 1997 May; 272(18):11702-5. PubMed ID: 9115221
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel domain of Ras and Rap1 that directs their differential subcellular localizations.
Nomura K; Kanemura H; Satoh T; Kataoka T
J Biol Chem; 2004 May; 279(21):22664-73. PubMed ID: 15031297
[TBL] [Abstract][Full Text] [Related]
13. Asparagine 26, glutamic acid 31, valine 45, and tyrosine 64 of Ras proteins are required for their oncogenicity.
Nur-E-Kamal MS; Sizeland A; D'Abaco G; Maruta H
J Biol Chem; 1992 Jan; 267(3):1415-8. PubMed ID: 1730690
[TBL] [Abstract][Full Text] [Related]
14. Association of the Ras-antagonistic Rap1/Krev-1 proteins with the Golgi complex.
Béranger F; Goud B; Tavitian A; de Gunzburg J
Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1606-10. PubMed ID: 1900364
[TBL] [Abstract][Full Text] [Related]
15. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
16. Post-translational modifications of p21rho proteins.
Adamson P; Marshall CJ; Hall A; Tilbrook PA
J Biol Chem; 1992 Oct; 267(28):20033-8. PubMed ID: 1400319
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic amino acid substitutions in the inhibitory rap-1A protein cause it to adopt a ras-p21-like conformation as computed using molecular dynamics.
Chen JM; Brandt-Rauf PW; Pincus MR
J Biomol Struct Dyn; 1996 Jun; 13(6):925-33. PubMed ID: 8832375
[TBL] [Abstract][Full Text] [Related]
18. Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor.
Herrmann C; Horn G; Spaargaren M; Wittinghofer A
J Biol Chem; 1996 Mar; 271(12):6794-800. PubMed ID: 8636102
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of GTPase activating protein stimulation of Ras-p21 GTPase by the Krev-1 gene product.
Frech M; John J; Pizon V; Chardin P; Tavitian A; Clark R; McCormick F; Wittinghofer A
Science; 1990 Jul; 249(4965):169-71. PubMed ID: 2164710
[TBL] [Abstract][Full Text] [Related]
20. smg/rap1/Krev-1 p21s inhibit the signal pathway to the c-fos promoter/enhancer from c-Ki-ras p21 but not from c-raf-1 kinase in NIH3T3 cells.
Sakoda T; Kaibuchi K; Kishi K; Kishida S; Doi K; Hoshino M; Hattori S; Takai Y
Oncogene; 1992 Sep; 7(9):1705-11. PubMed ID: 1323817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
